A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

PubWeight™: 2.49‹?› | Rank: Top 2%

🔗 View Article (PMC 2950613)

Published in Transplant Proc on December 01, 1991


J Fung1, K Abu-Elmagd, A Jain, R Gordon, A Tzakis, S Todo, S Takaya, M Alessiani, A Demetris, O Bronster

Author Affiliations

1: Dept. of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15213.

Articles citing this

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol (1995) 1.16

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant (1994) 1.15

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol (1993) 1.09

Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol (1995) 1.05

The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation (1993) 0.95

Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95

Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation (1994) 0.91

Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. Br J Pharmacol (1999) 0.86

Fluconazole therapy in transplant recipients receiving FK506. Transplantation (1994) 0.86

FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Recent advances in hepatic transplantation at the University of Pittsburgh. Clin Transpl (1993) 0.83

A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years. HPB (Oxford) (2012) 0.81

Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation (1994) 0.81

Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc (1993) 0.81

Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol (1993) 0.79

Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. Transplant Proc (1993) 0.79

Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78

Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 0.78

Liver transplantation at the University of Pittsburgh, 1984 to 1990. Clin Transpl (1991) 0.77

Liver disease. Postgrad Med J (1994) 0.76

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

Coronary Computed Tomography Angiography in Combination with Coronary Artery Calcium Scoring for the Preoperative Cardiac Evaluation of Liver Transplant Recipients. Biomed Res Int (2017) 0.75

Long-term insulin requirement after liver transplantation with FK 506 in American veterans. Transplant Proc (1993) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

Immunosuppression strategies after liver transplantation: a single centre experience in 57 liver transplant recipients. Indian J Surg (2008) 0.75

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Algebraic reconstruction techniques (ART) for three-dimensional electron microscopy and x-ray photography. J Theor Biol (1970) 6.86

Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Clinical, epidemiologic, and bacteriologic features. Ann Intern Med (1984) 6.54

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol (1999) 3.75

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49


Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75


Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem (1999) 2.72

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31